Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes pulmonary embolism compared with vitamin K antagonist (VKA) (very low certainty).
2 findings from 1 review
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic deep vein thrombosis ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes minor bleeding compared with direct oral anticoagulants (DOAC) (very low certainty).
1 finding from 1 review
RR 5 [0.31, 79.94]
1 study · 8 participants
Very low
Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes major bleeding compared with vitamin K antagonist (VKA) (very low certainty).
2 findings from 1 review
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes minor bleeding compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
Prostate cancer incidence · adults (aged at least 18 years)
Green tea extract supplementation showed no clear difference in prostate cancer incidence compared with placebo (low certainty).
1 finding from 1 review
Stomach cancer risk (18 studies) · adults (aged at least 18 years)
It is very uncertain whether highest changes stomach cancer risk (18 studies) compared with lowest green tea exposure (very low certainty).
1 finding from 1 review
RR 0.86 [0.74, 1.01]
438595 participants
Very low
Liver cancer risk (6 studies) · adults (aged at least 18 years)
Highest showed no clear difference in liver cancer risk (6 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.88 [0.68, 1.14]
198885 participants
Low
Pancreatic cancer risk (9 studies) · adults (aged at least 18 years)
Highest showed no clear difference in pancreatic cancer risk (9 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.88 [0.7, 1.1]
326564 participants
Low
Colorectal cancer risk (16 studies) · adults (aged at least 18 years)
Highest may leads to lower colorectal cancer risk (16 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.84 [0.74, 0.96]
610295 participants
Low
Colon cancer risk (10 studies) · adults (aged at least 18 years)
Highest may leads to lower colon cancer risk (10 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.89 [0.8, 0.98]
389974 participants
Low